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Abstract Various antihyperlipemic peroxisome proliferators
are known to be carcinogenic in rodents but not in human, other
primates and guinea pig, which species lost their ability to
synthesize ascorbate due to mutations in the gulonolactone
oxidase gene. Ascorbate synthesis is accompanied by H2O2
production, consequently its induction can be potentially harm-
ful; therefore, the in vivo effect of the peroxisome proliferator
clofibrate was investigated on gulonolactone oxidase expression
in mouse liver. Liver weights and peroxisomal protein contents
were increased upon clofibrate treatment. Elevated plasma
ascorbate concentrations were found in clofibrate-treated mice
due to the higher microsomal gulonolactone oxidase activities.
Remarkable gulonolactone oxidase activity appeared in the
peroxisomal fraction upon the treatment. Increased activity of
the enzyme was associated with an elevation of its mRNA level.
According to the present results the evolutionary loss of
gulonolactone oxidase may contribute to the explanation of the
missing carcinogenic effect of peroxisome proliferators in
humans.
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1. Introduction
Many human cancers can be caused by exposure to non-
genotoxic carcinogens. Non-genotoxic carcinogens stimulate
cell transformation indirectly, since they are not converted
to electrophilic derivatives. Among the most widespread
non-genotoxic carcinogens there is a group of compounds
collectively referred to as peroxisome proliferators. Peroxi-
some proliferators are a diverse class of chemicals, including
the lipid and cholesterol lowering ¢brate drugs (e.g. clo¢brate)
or endogenously occurring compounds (e.g. dehydroepian-
drosterone, leukotriene B4) [1]. Short-term administration of
peroxisome proliferators results in a marked increase in the
number and size of peroxisomes and an increase in liver size,
while long-term exposure to peroxisome proliferators results
in hepatocellular carcinomas [2,3]. A sustained increase in the
amount of peroxisomes induces hepatic oxidative stress, since
peroxisome proliferators cause a signi¢cant increase in the
levels of the H2O2-generating peroxisomal fatty acid L-oxida-
tion system in the liver [4]. Recent evidence indicates the pres-
ence of 8-hydroxydeoxyguanosine in DNA of rat liver chroni-
cally treated with peroxisome proliferators, suggesting a
possible basis for carcinogenesis of this class of carcinogens
[5^7].
However, there are remarkable species di¡erences in re-
sponse to peroxisome proliferators. Mice, rats, hamsters and
rabbits are responsive to these agents and in these species
hepatocellular adenomas and carcinomas develop upon
long-term administration of ¢brates [8^10]. In contrast, guin-
ea pigs, humans, and non-human primates including rhesus
monkeys exhibit peroxisome proliferation and enzyme induc-
tion, albeit to a lesser degree than in rodents, but show no
evidence of carcinogenesis after chronic exposure to ¢brate
drugs [8^10]. These species have another common attribute
besides the resistance against the carcinogenic e¡ect of ¢-
brates: they are unable to synthesize ascorbate due to multiple
mutations in the L-gulono-Q-lactone oxidase gene [11]. Gulono-
lactone oxidase is the ultimate enzyme of hepatic ascorbate
formation in ascorbate-synthesizing species. This £avoenzyme
is an integral membrane protein in the endoplasmic reticulum
of the liver [11]. In the course of its action equimolar amounts
of O2 and gulonolactone are consumed, and equimolar
amounts of ascorbate and H2O2 are produced [12,13]. The
regulation of its expression is poorly characterized. The mech-
anism by which humans, primates and guinea pigs are resist-
ant to the carcinogenic e¡ect of peroxisome proliferators is
not known. It is supposed that the insensitivity of these spe-
cies to the carcinogenic e¡ect of ¢brates may be related to the
evolutionary loss of H2O2-producing gulonolactone oxidase.
The question arises whether gulonolactone oxidase is induci-
ble by peroxisome proliferators in ascorbate-synthesizing spe-
cies. Therefore, the e¡ect of clo¢brate on gulonolactone oxi-
dase mRNA expression and activity both in microsomal and
peroxisomal fractions was investigated in murine liver.
2. Materials and methods
2.1. Materials
Alamethicin, clo¢brate, UDP-glucuronic acid (sodium salt), K,KP-
dipyridyl, L-gulono-Q-lactone, 4-morpholinopropanesulfonic acid
(MOPS) and Percoll were purchased from Sigma (St. Louis, MO,
USA). All other chemicals were of analytical grade purity or better.
WBondapak C18 HPLC column (average particle size 10 Wm, 300U4
mm I.D.) was obtained from MZ-Analysentechnik (Mainz, Ger-
many). Protein assay solution and 3MM ¢lter papers were purchased
from Bio-Rad Laboratories Ltd. (Budapest, Hungary). Hybond-N
Nylon membrane and and Hyper¢lm were provided by Amersham
International (Amersham, UK). K-32P-Labeled dCTP was obtained
from Institute of Isotopes Ltd. (Budapest, Hungary). High Prime
DNA labeling kit was purchased from Boehringer Mannheim (Mann-
heim, Germany).
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2.2. Treatment of mice
Animals involved in these study received humane care according to
the criteria outlined in the ‘Guide for the Care and Use of Laboratory
Animals’ prepared by the National Academy of Sciences and pub-
lished by the National Institutes of Health, USA. Sexually immature
(4^6-week-old) male mice of the C57BL/6 (B6) strain were provided
by Charles River Ltd. (Budapest, Hungary) and were housed with free
access to standard food in a rigidly controlled animal room of the
Department of Medical Chemistry, Semmelweis University of Medi-
cine (Budapest, Hungary). The inducing compound clo¢brate sus-
pended in isotonic saline (220 mg/kg body weight) was administered
daily by gastric intubation for 1 week before the mice were killed. The
control group of animals received isotonic saline. The daily dose of
clo¢brate was approximately as much as consumed by the animals in
the case of clo¢brate-containing diets applied in other studies [4].
2.3. Preparation of liver microsomes and peroxisomes
Liver microsomal vesicles were prepared from B6 male mice as
previously described [14]. Microsomes were resuspended at a concen-
tration of 40^60 mg of protein/ml in 20 mM MOPS (pH 7.2) contain-
ing 100 mM KCl, 20 mM NaCl, 3 mM MgCl2. Hepatic peroxisomal
vesicles were puri¢ed from the light mitochondrial fraction (V frac-
tion) of liver homogenates [15]. This fraction, enriched in lysosomes
and peroxisomes, was subfractionated by isopycnic centrifugation in
iso-osmotic self-generating Percoll gradients as previously described
[16]. Microsomal and peroxisomal suspensions were frozen and main-
tained under liquid nitrogen until used.
2.4. RNA extraction and Northern blotting with GLO probe
Total RNA was extracted from the liver of each mouse by the acid
guanidinium thiocyanate method [17]. The isolation of a rat GLO
cDNA was described previously [18]. A pUC19 fragment of the
cDNA, designated 15L [19], was kindly provided by Dr. Morimitsu
Nishikimi (Wakayama Medical College, Department of Biochemistry,
Wakayama, Japan). 15L and L-actin cDNA fragments were denatured
and labelled with [K-32P]dCTP using the High Prime DNA labelling
kit from Boehringer Mannheim. Then these were used to probe the
Northern blots. Northern blotting of RNA samples was performed
using essentially the method described by Sambrook et al. [20].
2.5. Measurement of enzyme activities
For the measurement of p-nitrophenyl UDP-glucuronosyltransfer-
ase activities microsomal and peroxisomal vesicles were permeabilized
by alamethicin using its optimally activating concentration (0.05 mg/
mg protein). Permeabilized vesicles were incubated in the presence of
5 mM UDP-glucuronic acid and 500 WM p-nitrophenyl for 30 min at
37‡C. Incubations were terminated by the addition of trichloroacetic
acid (TCA; 5% ¢nal concentration). The aglycone content of the
alkalinized deproteinized supernatants was measured spectrophoto-
metrically as previously described [21]. Plasma ascorbate contents
were measured by reverse phase HPLC following speci¢c sample prep-
aration as described earlier [22]. For the determination of gulonolac-
tone oxidase activities intact microsomal and peroxisomal vesicles
(usually 1 mg protein/ml) were incubated in the presence of 5 mM
gulonolactone for 30 min at 37‡C. Incubations were terminated by the
addition of 0.05 volume of 100% TCA. Ascorbate content was meas-
ured from deproteinized supernatants by the method of Omaye et al.
[23], based on the reduction of Fe3 with the oxidation of ascorbate
and the subsequent determination of the Fe2-K,KP-dipyridyl complex.
Catalase activities were measured according to [24].
2.6. Miscellaneous
Protein concentration of microsomes and peroxisomes was deter-
mined using Bio-Rad protein assay solution with bovine serum albu-
min as standard according to manufacturer’s instructions. All data are
expressed as means þ S.E.M. Statistical analysis was carried out using
Student’s t-test.
3. Results
3.1. The e¡ect of clo¢brate on microsomal and peroxisomal
gulonolactone oxidase activities
The e¡ect of clo¢brate treatment on microsomal and per-
oxisomal gulonolactone oxidase activities was investigated in
mice. There was no di¡erence in terminal body weight be-
tween control and treated animals after 1 week of clo¢brate
administration (Table 1). According to earlier observations
[2], in clo¢brate-treated animals liver weights and relative liver
weights were signi¢cantly higher compared to control mice.
Relative microsomal protein content was not a¡ected by clo-
¢brate, while relative peroxisomal protein content showed an
approximately 2.5-fold increase indicating the proliferation of
peroxisomes. At the same time plasma ascorbate concentra-
tion exhibited a more than two-fold elevation in clo¢brate-
treated mice (Table 1). It was supposed that the increase in
plasma ascorbate concentration was due to the stimulated
synthesis of ascorbate in the liver. The initial ascorbate con-
tents in both microsomes and peroxisomes were higher in
clo¢brate-treated mice compared to controls (Table 1). The
activity of microsomal gulonolactone oxidase was increased
approximately 8.5-fold by clo¢brate and simultaneously the
appearance of peroxisomal gulonolactone oxidase activity
was observed (Table 1). In control mouse liver only 0.1% of
the total gulonolactone oxidase activity was con¢ned to the
Table 1
The e¡ect of clo¢brate treatment on microsomal and peroxisomal enzyme activities
Control Clo¢brate-treated
Body weight (g) 22.7 þ 0.2 19.9 þ 3.4
Liver weight (mg) 1005 þ 51 1319 þ 38*
Relative liver weight (g liver/kg body weight) 41.1 þ 2.0 56.7 þ 0.9*
Relative peroxisomal protein content (Wg/g liver) 482 þ 64 1201 þ 98*
Relative microsomal protein content (Wg/g liver) 6819 þ 1199 6934 þ 226
Plasma ascorbate concentration (WM) 66.4 þ 4.2 135.2 þ 15.6*
Microsomal p-nitrophenyl UGT activity (nmol/min/mg protein) 29.58 þ 1.02 27.68 þ 0.60
Microsomal catalase activity (Wmol/min/mg protein) 0.48 þ 0.14 0.53 þ 0.09
Microsomal ascorbate content (nmol/mg protein) 15.2 þ 1.3 36.7 þ 4.6*
Microsomal gulonolactone oxidase activity (nmol/min/liver) 11.8 þ 2.0 101.0 þ 8.7*
Distribution of gulonolactone oxidase activity (%) 99.9 92.2
Peroxisomal catalase activity (Wmol/min/mg protein) 50.3 þ 9.2 114.3 þ 5.2*
Peroxisomal p-nitrophenyl UGT activity (nmol/min/mg protein) 0.07 þ 0.03 0.05 þ 0.01
Peroxisomal ascorbate content (nmol/mg protein) 4.64 þ 0.90 12.88 þ 2.43**
Peroxisomal gulonolactone oxidase activity (nmol/min/liver) 0.017 þ 0.002 8.59 þ 1.54*
Distribution of gulonolactone oxidase activity (%) 0.1 7.8
Data are expressed as means þ S.E.M. from 4^7 individual animals of each experimental group. Signi¢cant di¡erences from the corresponding
controls: **P6 0.05, *P6 0.01. Distribution of gulonolactone oxidase activities between microsomal and peroxisomal fractions was calculated
on the basis of the sum of these two values regarding it as the total (100%).
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peroxisomal fraction while in clo¢brate-treated liver almost
8% of the total activity was localized to them (Table 1).
The purity of microsomal and peroxisomal preparations
was also checked by measuring activities of the typical marker
enzymes in these fractions. The activity of a microsomal
marker enzyme, p-nitrophenyl UDP-glucuronosyltransferase,
was not changed by clo¢brate. Microsomes contained mini-
mal peroxisomal contamination, because catalase activities in
this fraction were lower than in peroxisomes by an order of
magnitude (Table 1). On the other hand, the high catalase
activities and the very low p-nitrophenyl UDP-glucuronosyl-
transferase activities in peroxisomes were indicative of the
purity of peroxisomal preparations (Table 1). According to
earlier ¢ndings, a modest elevation in catalase activity could
be observed after clo¢brate treatment, but at the same time
microsomal catalase activity was not changed (Table 1).
3.2. The e¡ect of clo¢brate treatment on hepatic gulonolactone
oxidase mRNA level
To determine whether the enhanced gulonolactone oxidase
activity in clo¢brate-treated mice occurs at the mRNA level,
total RNA was isolated from livers of both control and clo¢-
brate-treated animals. RNA samples were subjected to North-
ern hybridization with gulonolactone oxidase cDNA probe as
described. The autoradiograph showed an elevation of the
amount of gulonolactone oxidase mRNA in the liver of
mice treated with clo¢brate (Fig. 1).
4. Discussion
In the present study we demonstrated that gulonolactone
oxidase is induced in the endoplasmic reticulum of murine
liver by the peroxisome proliferator clo¢brate at the level of
mRNA (Fig. 1). Moreover, gulonolactone oxidase activity
appears in the proliferated peroxisomes. The upregulation of
gulonolactone oxidase could be due to the enhanced transcrip-
tion from its gene. There are several genes encoding peroxi-
somal fatty acid metabolizing enzymes which are inducible by
peroxisome proliferators [4]. Peroxisome proliferation is medi-
ated by peroxisome proliferator-activated receptor-K (PPARK)
[3]. Sequence analysis of the mouse gulonolactone oxidase
promoter is needed to demonstrate the involvement of PPARK
in the mechanism of induction.
Peroxisome proliferation is presumed to cause gene muta-
tions indirectly by increasing intracellular H2O2 [5^7]. In ro-
dent liver, peroxisome proliferators induce peroxisomal and
mitochondrial fatty acid L-oxidation simultaneously with the
H2O2-generating enzyme acyl-CoA oxidase but only modestly
induce catalase [1]. In addition, the activity of the other H2O2-
degrading enzyme, the cytoplasmic glutathione peroxidase, is
often depressed following long-term administration of peroxi-
some proliferators [1]. Thus, excess H2O2 could potentially
escape the peroxisomes and react with cellular macromole-
cules [1]. H2O2 can also activate several transcription factors
acting as a signal molecule or by redox mechanisms [25]. The
di¡erence between humans and rodents in the expression of
PPARK may explain partly the species di¡erences in the car-
cinogenic response to peroxisome proliferators. The evolu-
tionary loss of gulonolactone oxidase can give another, per-
haps more appropriate explanation for this di¡erence.
Gulonolactone oxidase may be regarded as an ectopic oxidase
which generates H2O2 in the endoplasmic reticulum rather
than in the usual place, in peroxisomes. The induced gulono-
lactone oxidase produces two metabolites: ascorbate and
H2O2. On the one hand the formation of ascorbate after clo-
¢brate treatment is a necessary process: (i) ascorbate is re-
quired for carnitine biosynthesis [26], thus it can promote
the transport of acyl-CoA groups into the mitochondria and
peroxisomes for the peroxisome proliferator-induced fatty
acid catabolizing enzymes; (ii) K-oxidation of fatty acids is
con¢ned to peroxisomes working at the highest rate in the
presence of ascorbate [27]. On the other hand, H2O2 can dis-
turb the cell cycle control, since there is no positive correlation
between the activities of H2O2-producing and H2O2-eliminat-
ing enzymes after clo¢brate treatment [1]. In the lack of gul-
onolactone oxidase the intracellular formation of hazardous
H2O2 is decreased, lowering the possibility of carcinogenesis
after the exposure to peroxisome proliferators. In the light of
this conclusion the evolutionary loss of gulonolactone oxidase
activity in humans, primates and guinea pigs could be advan-
tageous because the carcinogenic side e¡ect of peroxisome
proliferation, a physiological process, could be prevented.
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